Avant Immunotherapeutics Inc - Current report filing (8-K)
12 3월 2008 - 6:27AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
March 6,
2008
AVANT
IMMUNOTHERAPEUTICS, INC.
(Exact name of
registrant as specified in charter)
Delaware
|
|
0-15006
|
|
13-3191702
|
(State or other
jurisdiction
|
|
(Commission file
number)
|
|
(IRS employer
|
of
incorporation)
|
|
|
|
identification
no.)
|
119
Fourth Avenue
Needham,
Massachusetts 02494-2725
(Address of
principal executive offices) (Zip code)
Registrants
telephone number, including area code:
(781)
433-0771
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
|
|
|
o
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 2.01 Completion of Acquisition or Disposition of Assets.
Item 5.01 Changes in Control of Registrant.
On
March 7, 2008, AVANT Immunotherapeutics, Inc. (AVANT) announced it
had closed the merger pursuant to the Agreement and Plan of Merger dated October 19,
2007 (the Merger Agreement) by and among AVANT, Callisto Merger Corporation (Merger
Sub), a wholly owned subsidiary of AVANT, and Celldex Therapeutics, Inc.
(Celldex). Pursuant to the terms of the merger agreement, Merger Sub merged
with and into Celldex, with Celldex as the surviving company and a wholly-owned
subsidiary of AVANT. The total value of the transaction is approximately $75
million. Approximately 104.8 million shares (on a pre-split basis) are being
issued to the former Celldex shareholders in connection with the merger.
Celldex
shareholders will receive approximately 4.96 shares of AVANT common stock in
exchange for each share of Celldex common stock and Class A common stock
they own. AVANT stockholders will retain 42% of, and the former Celldex
stockholders will own 58% of, the outstanding shares of AVANTs common stock on
a fully-diluted basis. AVANT will also assume all of Celldexs stock options
outstanding at the time of the merger.
Item 3.01 Notice of Delisting or Failure to Satisfy a
Continued Listing Rule or Standard; Transfer of Listing.
On February 29, 2008, AVANT received notice from the Listing
Qualifications Department of The NASDAQ Stock Market indicating that AVANT has
been approved to list its common stock on The NASDAQ Global Market. AVANTs
common stock began trading on The NASDAQ Global Market, and ceased trading on
The NASDAQ Capital Market, at the opening of business on March 10, 2008.
Item 3.03. Material Modification to Rights of Security
Holders
In
connection with the closing of the merger, AVANT and Computershare Trust
Company, N.A, as Rights Agent, entered into Amendment No. 2 to the Rights
Agreement, dated as of March 7, 2008 (the
Rights Amendment
). The
Amendment provides that: (i) the definition of Grandfathered Percentage
shall include the percentage of post-merger ownership of AVANTs common shares
plus an additional 1/2 percent beneficially owned by Medarex, Inc. and
Lorantis Holdings Limited respectively as of immediately following the
effective time of the merger and (ii) the definition of Grandfathered
Person shall include Medarex, Inc. and Lorantis Holdings Limited.
The
foregoing description of the Rights Amendment is qualified in its entirety by
reference to such Rights Amendment, which was filed as Exhibit 10.1 to the
Form 8-A/A filed by AVANT with the Securities and Exchange Commission on March 7,
2008, and which is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Directors
Pursuant to the terms of the Merger Agreement, and
as stated in the proxy statement/prospectus set forth in a registration
statement on Form S-4 as filed with the Securities and Exchange Commission
on December 21, 2007, as amended (the Proxy Statement), a
ll options to
purchase Celldex common stock outstanding at the effective time of the merger
granted under the Celldexs 2005 Equity Incentive Plan
2
(the
Celldex Plan) have been assumed by AVANT and the following individuals have been elected to the Board of Directors of
AVANT (the Board) as of March 7, 2008:
Charles
Schaler,
who will be Chairman of the Board, has been named
chair of the Compensation Committee and
has been named to the Nominating and Corporate Governance Committee of the
Board. Mr. Schaller had options granted under the Celldex Plan
which were outstanding at the effective time of the merger and have been
assumed by AVANT representing options for 14,882 AVANT shares on a post-split-as-converted basis;
George
Elston
has been named to the Audit
Committee of the Board. Mr. Elston had options granted under the Celldex
Plan which were outstanding at the effective time of the merger and have been
assumed by AVANT representing options for 17,879 AVANT shares on a post-split-as-converted basis;
Herbert
Conrad
has been named chair of the Nominating
and Corporate Governance Committee. Mr. Conrad had options granted under
the Celldex Plan which were outstanding at the effective time of the
merger and have been assumed by AVANT representing options for 17,879 AVANT shares on a
post-split-as-converted basis; and
Dr. Rajesh B.
Parekh
has been named to the Compensation
Committee. Dr. Parekh had options granted under the Celldex Plan
which were outstanding at the effective time of the merger and have been
assumed by AVANT representing options for 17,879 AVANT shares on a post-split-as-converted basis.
Officer Anthony S. Marucci
Pursuant to the terms of the Merger Agreement, and
as stated in the Proxy Statement, as of March 7, 2008
the Board
appointed Anthony S. Marucci as
the Executive Vice President, Corporate Development of AVANT. Information
concerning Mr. Marucci, including the positions he holds with AVANT and
its subsidiaries and his business experience during the past five years, is
included in the Proxy Statement, and such information is incorporated by
reference herein. Mr. Marucci, age 45, is employed pursuant to an
employment agreement with Celldex. In addition, Mr. Marucci had options granted under the Celldex
Plan which were outstanding at the effective time of the merger and have been
assumed by AVANT representing options for 254,243 AVANT shares on a post-split-as-converted basis. Mr. Maruccis
employment agreement provides him with certain benefits in the event he is
terminated without cause, Mr. Marucci terminates employment with good
reason, or Mr. Marucci terminates his employment within one year following
the consummation of the merger. Information concerning Mr. Maruccis
employment agreement is included in the Proxy Statement under the heading Celldexs
Compensation Discussion and Analysis, subheading Potential Payments Upon
Termination of Employment or Change in Control, and such information is
incorporated by reference herein.
Item 8.01 Other Events.
Shareholder Meeting
At
the special meeting of AVANT shareholders held on March 6, 2008 in
connection with the merger, shareholders approved four proposals: (i) the
issuance of shares of AVANT common stock pursuant to the merger agreement in
the amount necessary to result in the Celldex stockholders owning 58% of AVANT
common stock on a fully diluted basis, (ii) an amendment to AVANTs Third
Restated Certificate of Incorporation to increase the number of authorized
shares to 300,000,000, (iii) an amendment to AVANTs Third Restated
Certificate of Incorporation to effect a reverse stock split in a ratio ranging
from one-for-twelve to one-for-twenty of all issued and outstanding shares of
AVANT
3
common
stock, the final ratio to be determined within the discretion of the Board and (iv) adoption
of the 2008 stock option and incentive plan.
Reverse
Stock Split
The
Board has approved a 1-for-12 reverse stock split of AVANTs common stock,
which became effective as of March 7, 2008. As a result of the reverse
stock split, each twelve shares of AVANT common stock will be combined and
reclassified into one share of AVANT common stock and the total number of
shares outstanding will be reduced from approximately 180 million shares
(including the shares issued to Celldex shareholders in connection with the
merger) to approximately 14 million shares.
The AVANT common stock
will trade under the symbol AVAND for 20 trading days beginning on March 10,
2008 to designate that it is trading on a post-reverse split basis, and will
resume trading under the symbol AVAN after the 20-day period has expired.
Press Release
On March 7, 2008
AVANT issued a press release announcing the completed merger with Celldex, the
1-12 reverse stock split, and the results of the shareholder meeting. A copy of
the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
|
|
Description of Exhibit
|
|
|
|
3.1
|
|
Fourth
Certificate of Amendment of Third Restated Certificate of Incorporation of
AVANT Immunotherapeutics, Inc.
|
3.2
|
|
Fifth
Certificate of Amendment of Third Restated Certificate of Incorporation of
AVANT Immunotherapeutics, Inc.
|
99.1
|
|
AVANT
Immunotherapeutics, Inc. Press Release, dated March 7, 2008
|
4
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, hereunto duly authorized.
|
AVANT
IMMUNOTHERAPEUTICS, INC.
|
|
|
|
Dated: March 11,
2008
|
By:
|
/s/ Avery W. Catlin
|
|
Name: Avery W. Catlin
|
|
Title: Senior
Vice President and Chief Financial Officer
|
|
|
5
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024